Oxford BioTheraputics Names Abderrahim Fandi as CMO

Abderrahim Fandi, formerly of Celgene, has joined Oxford BioTherapeutics as the company’s CMO. His position will be responsible for developing OBT’s immuno-oncology candidates.

Rahim brings a wealth of drug development expertise to OBT, which will significantly benefit the company as we move our clinical development program forward in the United States for MEN1309, our novel ADC therapy [that’s] currently undergoing clinical testing in Europe,” said OBT CEO Christian Rohlff in a recent statement.[1]

The press release announces that Dr. Fandi has led the development of several oncology compounds and participated in successful regulatory interactions, including many with the FDA. He has also held positions at Novartis, BMS, AstraZeneca, and Sanofi Aventis, and has contributed to over 100 peer-reviewed publications and abstracts. In addition, he has served as first author in lead journals, including the Journal of Clinical Oncology.

To read the full press release from Oxford BioTherapeutics, visit PharmiWeb.com.

 

[1] https://www.pharmiweb.com/pressreleases/pressrel.asp?ROW_ID=267248

Follow us on social media for the latest updates in B2B!

Image

Latest

employer-sponsored apprenticeships
The Degree That Pays You Back: How Employer-Sponsored Apprenticeships Are Rewriting Higher Ed
March 9, 2026

Higher education is under pressure. Over the past few years, public confidence in the value of a four-year degree has declined significantly, with fewer Americans expressing a strong belief that traditional higher education delivers a worthwhile return on investment. At the same time, employers consistently report that graduates lack job-ready skills—particularly the “durable skills”…

Read More
Denial Data
Turning Denial Data Into Action: How Healthcare Organizations Can Fight Back Against Payer Denials
March 5, 2026

Healthcare providers across the U.S. are facing a growing wave of claim denials that is putting pressure on already strained hospital finances. Industry research from the American Hospital Association shows that nearly 15% of medical claims submitted to private payers are initially denied, forcing hospitals and health systems to spend about $19.7 billion annually attempting…

Read More
Jabra
ISE 2026: Jabra Unveils Scalable Room Solutions for the Hybrid Workplace
March 5, 2026

At ISE 2026, Jabra highlighted how meeting technology is evolving to support the realities of hybrid work, where the experience must be equally effective for people inside and outside the room. In a conversation with Craig Durr, Chief Analyst and Founder of The Collab Collective, Jabra’s VP of Video Product Olly Henderson explained that…

Read More
Marketing AI Pulse
The Marketing AI Pulse Brief for Feb 2026: Trust in the World of LLM Ads, OpenClaw, Reddit & More!
March 3, 2026

Starting in 2026, The Marketing AI SparkCast alternates between the Marketing AI Pulse Monthly Brief and in-depth interviews with leading marketing AI innovators. This episode is the February 2026 edition of the Monthly Brief and focuses on trust and authenticity in an AI-driven world. Aby Varma and Matt Cyr explore the emergence of advertising inside…

Read More